300015 爱尔眼科
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入18,344,2874.92%22,352,60520,982,89420,367,15716,109,947
减:营业总成本13,914,5804.84%17,711,12616,628,94215,113,23312,152,478
    其中:营业成本9,723,9959.64%11,821,51210,886,54910,021,9757,980,389
               财务费用258,23288.94%175,995214,29873,6286,655
               资产减值损失(150,092)22,469.66%(157,139)(187,757)(383,606)(95,464)
公允价值变动收益(49,172)-335.43%98,290334,398(79,423)(356,890)
投资收益16,531-26.99%75,143213,22046,52343,910
    其中:对联营企业和合营企业的投资收益(17,095)--338----(3)
营业利润4,231,4192.10%4,603,0954,824,9174,947,9473,534,500
利润总额3,982,359-1.41%4,425,1354,594,2824,551,0193,335,056
减:所得税费用1,425,762112.05%951,916858,153895,023646,059
净利润2,556,597-24.07%3,473,2193,736,1303,655,9962,688,997
减:非控股权益258,8752.57%232,960180,074297,124164,766
股东净利润2,297,722-26.23%3,240,2593,556,0563,358,8722,524,231

市场价值指针
每股收益 (元) *0.247-26.65%0.3500.3850.3640.279
每股派息 (元) *----0.1800.1600.1500.100
每股净资产 (元) *2.4391.37%2.3562.2212.0212.323
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容